Skip To Main Content
J. Barriuso on Muck Rack

J. Barriuso

As seen in: Annals of Oncology, Clinical Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with J.

Contact J., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Methodological and reporting standards for quality of life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit

|
By S.F. Oosting, J. Barriuso, A. Bottomley, European Organisation
| annalsofoncology.org
Article Info Publication History Accepted: December 10, 2022 Received in revised form: November 24, 2022 Received: May 2, 2022 Publication stage In Press Journal Pre-Proof Footnotes *The individual names of the members of the ESMO-MCBS Working Group and Extended Working Group who are not listed as authors are provided in the Appendix A at the end of the main text. FUNDING This study was not supported financially.
Open in Who Shared Issue with article?

Obesity and Cancer Treatment Outcomes: Interpreting the Complex Evidence

|
By of Manchester, of Salford Manchester, J. Barriuso, H. Guo, C.G.V. Slawinski
| Clinical Oncology Verified
World Health Organization Obesity and overweight. World Health Organisation, 2018 () Renehan A.G. Zwahlen M. Egger M. Adiposity and cancer risk: new mechanistic insights from epidemiology. Nat Rev Cancer. 2015; 15: 484-498https://doi.org/10.1038/nrc3967 Iyengar N.M. Gucalp A. Dannenberg A.J. Hudis C.A. Obesity and cancer mechanisms: tumor microenvironment and inflammation. J Clin Oncol.
Open in Who Shared Issue with article?

Phase II study of everolimus (EVL) and octreotide (OCT) LAR in patients with non-functioning gastrointestinal neuroendocrine tumours (GI-NETs): EVERLAR study

|
By D. Castellano, J. Capdevila, A. Teulé, J. Barriuso
| Annals of Oncology Verified
Phase II study of everolimus (EVL) and octreotide (OCT) LAR in patients with non-functioning gastrointestinal neuroendocrine tumours (GI-NETs): EVERLAR study J. Capdevila1, A. Teulé2, J. Barriuso3, D. Castellano4, C. Lopez5, J.L. Manzano6, V. Alonso7, R. Garcia-Carbonero8, E. Dotor9, I. Matos1, A. Custodio3, O. Casanovas2 and R.
Open in Who Shared Issue with article?
See all 3 articles